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1 Introduction: 
1.1 The Blood-Brain Barrier 
1.1.1 Function of the Blood-Brain Barrier 
 
The Blood-Brain Barrier (BBB) is a complex structure of capillary endothelial cells which 
prevents damaging and toxic substances from getting into the brain. However, it also 
differentiates between substrates required by the central nervous system (CNS) and 
unwanted agents such as xenobiotics and microorganisms (Mensch, Oyarzabal et al. 2009). It 
also makes sure the brain is cleared of metabolites, waste products and unwanted molecules 
(Abbott, Ronnback et al. 2006). Additionally, the BBB plays an important role in maintaining 
the homeostatic regulation of the brain microenvironment, being an essential requirement 
for the healthy activity of the neurons (Abbott 2002). This function is especially important as 
changes in the ionic composition of the blood that occur after meals or exercise, would 
significantly damage synaptic and axonal signalling. Subsequently, the BBB separates two 
pools of neurotransmitters, peripheral and central, making it possible for the body to use 
similar agents in different concentrations without having an effect on each other (Abbott, 
Ronnback et al. 2006). 
 
1.1.2 History 
 
The first empirical observation of the BBB was documented by Paul Ehrlich, a German 
scientist and physician, in 1885. He intravenously injected dyes which are used for vital 
staining in cells, in rats and discovered that they would stain all the organs of the body 
except for the brain. However Ehrlich did not draw the right conclusion as he thought the 
brain had less affinity to the dye than the other parts of the body. His student Edwin 
Goldmann continued the experiments and injected Trypan blue intravenously. He made the 
same observation, but additionally he performed experiments where he injected the dye 
into the cerebrospinal fluid. Importantly only the brain and the CSF were dyed, the other 
organs were unstained. Upon this result, Goldmann presumed some kind of barrier must  
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exist between the blood and the brain. But he was not the only one, who had a closer look at 
this matter, Max Lewandowsky, a German neurologist, performed experiments with 
Potassium hexocyanidoferrate(II) and was the first to introduce the term “Blood-Brain 
Barrier”. In the 1930s a differentiation between BBB and blood-CSF barrier was made, but it 
was not until the 1960s that scanning electron microscopy gave proof of the existence of the 
BBB.  
 
1.1.3 Structure and cell types 
 
The BBB is formed mainly by three 
different cell types (Fig. 1): endothelial 
cells, which line the cerebral capillaries, 
astrocytes, to envelope the capillary 
endothelium and in between pericytes, 
which work as connective tissue. Due to 
their interaction in health and injury 
they are seen as a functional unit, 
called the neurovascular unit (Cecchelli, 
Berezowski et al. 2007). The cerebral 
endothelial cells are different from  
those in the periphery in two main 
ways. Firstly they form tight junctions, a 
key element of the BBB which gives the 
BBB its physical “barrier” properties, 
and secondly they have a relatively low 
rate of fluid-endocytosis (Rubin, Hall et al. 1991). Additionally, they lack fenestrations and 
have increased mitochondrial content (Hawkins and Davis 2005). All of these features ensure 
the barrier function of the BBB. 
Astrocyte endfeet cover more than 99% of the endothelial cells’ abluminal side. They play an 
important role in the differentiation of the BBB and heighten the restrictive barrier. In vitro 
Fig. 1 schematic representation of the neurovascular unit, modified 
from (Abbott, Patabendige et al. 2010) 
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studies have proved that endothelial cells have an increased transendothelial electrical 
resistance (TEER) when co-cultured with astrocytes. The TEER displays the tightness of a cell 
layer (see section 1.1.4) and is used to characterise the ion permeability in cerebral blood 
vessels but also epithelia (Butt, Jones et al. 1990). The increased TEER can be partially 
explained by the induction of tight junctional properties by soluble astrocytic paracrine 
factors. However, the role of the astrocytic endfeet in maintaining BBB integrity is not yet 
fully understood. Furthermore astrocytes can also modulate enzymes and transporter 
systems such as the multi-drug resistance efflux transporter Pgp (P-glycoprotein) and the 
brain glucose transporter GLUT-1 (Smith and Gumbleton 2006). 
Other than the endothelial cells and the astrocytes, pericytes, the third component of the 
neurovascular unit, have also yet to have their role in the BBB uncovered. They can be seen 
as the smooth muscle cell of the unit and appear to stabilize it. In addition to providing 
structural integrity, they apparently play a role in the regulation of the cerebral blood flow 
(Smith and Gumbleton 2006). In pathological conditions e.g. hypoxia or brain injury, where 
the BBB integrity is decreased, pericytes migrate away from the microvessels. Therefore it is 
assumed that these two phenomena are related, but it has not yet been verified if the 
pericyte migration has a causative role in BBB deficiency (Hawkins and Davis 2005). Further 
pericytes seem to play a key role in the formation of new vessels and they express a variety 
of metabolising enzymes and scavenging receptors which distinguishes their role as an 
enzymatic barrier and in neuroimmunity (Smith and Gumbleton 2006). 
 
1.1.4 Features of the BBB – junctional complexes 
 
The BBB has several characteristics which give the highly specialised endothelium strong 
barrier. First of all the tight junctions (TJs) and in addition adherens junctions (AJs) ensure 
that there is very limited paracellular traffic of molecules, only small gaseous molecules like 
O2 and CO2 can pass the BBB freely (Abbott, Ronnback et al. 2006). The presence of gap 
junctions has not yet been confirmed (Hawkins and Davis 2005). Consequently, most of the 
substances which cross the BBB have to take a transcellular pathway and use transporters or 
other ways (see 1.1.5) as the route of simple diffusion is not available for all of them 
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(Hawkins and Davis 2005). Also waste products from the brain require efflux into the blood 
and specific mechanisms exist at the BBB to allow for this. 
Tight junctions are the bridging elements that link the endothelial cells and therefore 
provide a solid bloodvessel (Stamatovic, Keep et al. 2008).  
By using the method of freeze-fracture techniques the morphological structure of the TJs 
can be seen. These replicas show the complexity and the association with the inner (P-face) 
or outer (E-face) lipidic layer of the membrane. As a result it is visible, that in brain 
capillaries, the TJs associate in the same degree with both faces, whereas TJs in peripheral 
endothelial cells prefer the E-face. This observation is another proof for the tightness of the 
barrier (Wolburg, Noell et al. 2009). 
The TJs have a very complex structure (Fig. 2) formed by various plasma membrane proteins 
to link and connect the endothelial cells. The most important ones are the claudins, occludin, 
junctional adhesion molecules (JAMs) and cytoplasmic proteins, such as zonula occludens 
proteins (ZO) and cingulin (Ueno 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Representation of the main elements forming a tight junction. Modified from 
(Hawkins and Davis 2005) 
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Claudins are the core element of the TJs, they enable the high TEER and form the principal 
hurdle (Hawkins and Davis 2005; Bernacki, Dobrowolska et al. 2008). To date 24 different 
claudins have been described in mammals, their size varies between 20 and 24 kDa, but 
structurally they show the same elements: two extracellular loops, four transmembrane 
domains and both C- and N-Terminus in the cytoplasm (Stamatovic, Keep et al. 2008). The 
extracellular loops correspond with each other in both a homophilic and a heterophilic way 
(Hawkins and Davis 2005). One of them controls paracellular charge selectivity whereas the 
other one is a receptor for a bacterial toxin. In the cytoplasm the C-Terminus links the 
protein with ZO-1, ZO-2 and ZO-3 (Hawkins and Davis 2005; Bernacki, Dobrowolska et al. 
2008). Of the mentioned 24 claudins, the BBB shows claudin-1, claudin-3 and claudin-5, 
although the presence of claudin-1 has been questioned recently (Hawkins and Davis 2005). 
In addition to this “backbone”, occludin, another transmembrane, protein helps to maintain 
the barrier. It was the first to be discovered and shares some structural features but no 
sequence homology with the claudin family (Wolburg, Noell et al. 2009). Occludin has a size 
of around 65 kDa and its structure includes four transmembrane regions, two extracellular 
loops and one intracellular short turn. Both C- and N-terminus are situated in the cytoplasm. 
The two extracellular loops again provide the TEER and the adhesion between the cells. At 
the C-terminal end it is connected with ZO-1, ZO-2 and ZO-3, the N-terminus is important for 
the role of an adhesion molecule (Stamatovic, Keep et al. 2008). Nevertheless, it has been 
proved in various studies, that a deficiency of occludin does not influence the formation of 
TJs. It has more of a regulatory purpose although a reduced expression correlates with 
disrupted BBB function in several diseases (Hawkins and Davis 2005).  
The third element of the TJs, providing with bonding character are the junctional adhesion 
molecules (JAMs). Their exact function in the grown BBB is still largely unknown, but it is 
assumed that they play a role in the early attachment of vicinal cells membranes (Hawkins 
and Davis 2005). JAMs belong to the group of immunoglobulins with a size of about 40 kDa. 
Structurally they have a single transmembrane domain, which is linked to an extracellular 
strand with two loops (Bernacki, Dobrowolska et al. 2008). The C-terminal end is in the 
cytoplasm again, but the N-terminus lies in the extracellular space (Stamatovic, Keep et al. 
2008). Three types have been distinguished: JAM-1, -2 and -3 (Bernacki, Dobrowolska et al. 
2008). 
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Finally there is the group of cytoplasmic proteins, for instance zonula occludens proteins or 
cingulin. In general they help maintaining the tight junctions and provide structural support. 
ZOs (ZO-1, -2 and -3 are known by now) are linking with claudins, occludin and JAM, Cingulin 
on the other hand binds to ZOs and myosin. Altogether they connect the transmembrane 
proteins with the cytoskeleton (Bernacki, Dobrowolska et al. 2008).  
Adherens junctions have the same purpose as well as arbitrating the adhesion of the 
endothelial cells to each other, upholding their contact and initiating cell polarity. The major 
component of AJ is vascular endothelial (VE)-cadherin, a Ca2+-regulated protein, which 
mediates cell-cell adhesion of bordering cells by homophilic interaction of the extracellular 
domains of proteins (Hawkins and Davis 2005). Cadherin is linked with catenin and other 
related proteins. In that way the membrane proteins are, through the cytoplasmic proteins, 
connected with the actin cytoskeleton, which is the backbone of the cell (Ueno 2009). 
Though the AJs contribute to the tightness, it is the tight junctions that provide most of it. 
Characteristics here are the high transendothelial electrical resistance (TEER) of about 1500 
– 2000 Ω.cm2, peripheral capillaries show a TEER of 3 – 33 Ω.cm2, and the dependence on a 
stable Ca2+ concentration to maintain the integrity (Bernacki, Dobrowolska et al. 2008; 
Stamatovic, Keep et al. 2008). Therefore changes in the electrolyte household can influence 
the barrier delicately and decrease permeability.  On the contrary elevated cATP levels in the 
cell induce the forming of fusion points and fasten TJs (Bernacki, Dobrowolska et al. 2008). 
 
1.1.5 Pathways across the BBB and their mechanisms 
 
Due to the above-mentioned physiologically restricting structure, most of the pathways 
across the BBB are transporter-mediated. 
Paracellular transport is highly restrictive and it is controlled by electrochemical, hydrostatic 
and osmotic gradients. In cases of higher paracellular transport the junctional complexes are 
being altered and form minute intercellular gaps (Stamatovic, Keep et al. 2008). This 
situation can occur in case of stroke or epileptogenic foci (Abbott, Patabendige et al. 2010). 
In a situation like that albumin (and other plasma proteins), fluids and leukocytes are able to 
pass the barrier (Stamatovic, Keep et al. 2008). 
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On the other hand transcellular pathways can be classified in passive diffusion, transport 
proteins, receptor-mediated transcytosis and adsorptive transcytosis (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
First there is the way of passive diffusion, which can only be used by small lipophilic 
molecules. Criteria for predicting a substance’s ability to pass the barrier passively are the 
logD (partition coefficient between octanol and buffer at pH 7.4), the polar surface area 
(PSA) and the tendency of the molecule to form hydrogen bonds. In general a higher logD 
correlates with better permeation, a PSA greater than 80 Å2 and the ability to form more 
than 6 hydrogen bonds decrease the possibility for passive diffusion. Additionally rotatable 
bonds and a molecular weight of more than 450 Da appear to restrain BBB permeability. 
Nevertheless, these are only guidelines and there are always exceptions to the rule. Apart 
from small, lipophilic substances, two essential gases, oxygen and carbon dioxide, diffuse 
passively along their concentration gradients. Hence, if the cerebral blood flow is ensured, 
the oxygen supply and carbon dioxide removal are guaranteed (Abbott, Patabendige et al. 
2010).  
Fig. 3 different pathways across the BBB, from (Abbott, Ronnback et al. 2006), 
further explanation in the text 
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The next pathway is the one via transport proteins which is, along with the mechanism of 
receptor-mediated transcytosis, responsible for the uptake of substrates and the efflux of 
unwanted substances (Abbott and Romero 1996). Drug transporters can be divided into two 
major families, the ATP-binding cassette transporters (ABC) and the solute carrier-family 
(SLC) (Eyal, Hsiao et al. 2009). 
ABC-transporters characteristically need ATP to transport their substrates against 
concentration gradients. The most prominent member here is Pgp, others are multidrug 
resistance-associated proteins (MRPs) and breast cancer resistance protein (BCRP). Pgp is an 
efflux pump located at the luminal side of the capillaries with a wide range of substrates, for 
instance the cytostatics, vincristin and vinblastin, as well as anti-retroviral agents like 
indinavir and opioids such as morphine and loperamide (Abbott and Romero 1996; Eyal, 
Hsiao et al. 2009). These substances all penetrate the membrane of the capillaries, but are 
removed by Pgp. This explains why their concentration in the brain is much lower than 
would be expected from their logD values (Abbott, Patabendige et al. 2010). However Pgp 
not only has substrates, but inhibitors too, for example the cardiac agent verapamil and the 
immunosuppressant cyclosporine. Therefore the option of inhibiting Pgp transiently to 
provide greater uptake of several drugs into the brain can be considered as a therapeutic 
strategy for diseases like epilepsy. Nevertheless, the hazards of such a modulation have to 
be taken into account (Loscher and Potschka 2005). The second prominent member of the 
ABC-transporter family, which is located at the luminal membrane is the breast cancer 
resistance protein (BCRP). Many substrates overlap with the ones of Pgp, but in contrast 
BCRP is upregulated in tumour cells (Eyal, Hsiao et al. 2009). Finally there is the group of 
MRPs which are present at the luminal (MRP2, MRP4) and the basolateral (MRP1, MRP3, 
MRP5, MRP6) membrane (Loscher and Potschka 2005). Most of these proteins are organic 
anion transporters, but there are neutral substrates too. Additionally to ATP, some of them 
need cofactors for the transport. Again substrates overlap with the ones of Pgp and BCRP 
(Eyal, Hsiao et al. 2009).  
In contrast to the ABC-transporters, members of the SLC-family do not need ATP to transport 
their substrates. Currently there are 43 subfamilies in the human body known which have 
mostly polar and essential substrates like glucose or amino acids (Kusuhara and Sugiyama 
2005; Abbott, Patabendige et al. 2010). The SLC-family members expressed at the BBB play a 
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greater role in supplying the brain with nutrients, rather than keeping unwanted agents out. 
Examples here include the glucose transporter GLUT-1 cationic amino acid transporters 
(CAT1 and CAT3) and the large neutral amino acid transporter (system L) (Abbott, 
Patabendige et al. 2010). The glucose transporter is of special importance because of the 
high need for glucose in the brain. There are two isoforms selectively expressed in brain 
capillaries, GLUT-1 and GLUT-3 (Guo, Geng et al. 2005; Wolburg, Noell et al. 2009). The 
expression is regulated by metabolic demand and regional differences in glucose need. 
Therefore a malfunction or dysregulation following or caused by different diseases can 
become rate limiting for the metabolism in the brain. Diseases like that are Alzheimer’s 
disease, ischemia or epilepsy (Guo, Geng et al. 2005).  
Third in the possibilities of transcellular pathways is receptor-mediated transcytosis. In this 
case the molecule binds to a specific receptor which activates an endocytotic event. First 
receptor and ligand cluster together, then a caveolus is formed which leads to the shaping of 
a vesicle with both receptor and ligand in it. Inside this vesicle they are moved to the other 
side of the cell and exocytosed (Abbott, Patabendige et al. 2010). This pathway is for large 
molecules like insulin, albumin, low- and high-density lipoprotein or advanced glycation end 
products (Wolburg, Noell et al. 2009).  
Finally there is another type of transcytosis, called adsorptive transcytosis. As well as with 
receptor-mediated transcytosis, the substrates in adsorptive transcytosis are 
macromolecules such as cationised albumin or cell penetrating peptides. But unlike 
receptor-mediated transcytosis, the transported molecule has to show excessive positive 
charging to form the caveolus and later the vesicle (Abbott, Patabendige et al. 2010). 
In both cases the vesicles’ contents have to be kept safe from being lysed by degradative 
mechanisms such as lysosomes. It appears to be a speciality in brain endothelial cells to 
actively route the vesicles away from acidic lysosomes as in peripheral tissues endosomes 
are very often directed there for breakdown (Abbott, Patabendige et al. 2010). 
 
 
 
 
22 
 
1.1.6 Role as metabolic barrier 
 
Another important function of the BBB are its metabolic properties. These restrict traffic 
across the BBB even more than just the physical barrier, as substances may enter the 
endothelial cells but can be metabolised and therefore made ineffective. Up until now it has 
been shown that in rodent brains enzymes such as monoamine oxidase, catechol-O-methyl 
transferase or epoxide hydrolase act at the blood-brain interface. Less evidence has been 
found that monoamine oxidase, epoxide hydrolase and several cytochromes such as CYP1B1 
appear at the human BBB (Eyal, Hsiao et al. 2009). Nevertheless, the levels of cytochromes in 
the BBB are generally 0.5-2% of those in the liver (Carvey, Hendey et al. 2009). Apart from 
that the cytochromes possibly play a major role in regulating endogenous GABA (γ-
aminobutyric acid). Finally the cytochromes which are present in the BBB appear to be 
inducible, as the ones in the liver are (Carvey, Hendey et al. 2009). 
 
1.1.7 Different approaches in studying the BBB 
 
Recently, as technology has improved, research on the BBB has increased and several 
models have been designed to explore different aspects of the BBB. In general there are 
three major approaches for studying the BBB: in vivo, in vitro and in silico.  
In vivo 
Although in vitro and in silico methods cost less money and often do not require as much 
time and effort, in vivo experiments remain an important part of BBB research as they give 
the most reliable reference information to validate and test other models. There is a broad 
range of techniques which can be separated into two major groups: the first is based on 
equilibrium studies between brain and blood such as the extent of brain penetration and the 
second is focused on kinetic parameters such as permeability X surface area product. 
Another classification can be made by dividing the techniques into invasive and non-invasive. 
Only the non-invasive experiments can be done on humans as they permit to measure the 
brain uptake along with pharmacokinetic parameters without harming the body (Mensch, 
Oyarzabal et al. 2009). Most of the invasive methods imply injecting the drug in question 
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along with a vascular space marker, for instance tritium-labelled inulin or technetium-
marked albumin, to ensure the BBB is intact (Kakee, Terasaki et al. 1997; Pan, Banks et al. 
1997). These markers typically have low permeability across the BBB and increased values 
indicate a loss of BBB integrity (Bickel 2005; Sanderson, Dogruel et al. 2009). The injection is 
made intravenously in the carotid artery, which is used for example with the brain uptake 
index technique or in situ brain perfusion. After the given perfusion time the animal is 
decapitated and the amount of drug in the different brain regions is analysed (Mensch, 
Oyarzabal et al. 2009). Another method is the intracerebral microdialysis, which is 
performed on a living animal. A probe is implanted in the extracellular space of the brain. 
Here it is possible to choose which region is analysed by selecting where to place the probe. 
It consists of a semi-permeable membrane which is perfused with a physiological medium. 
The drug in question can be administered orally, intravenously or subcutaneously and by 
collecting the perfusate at the membrane it is determined how much of the drug has 
entered the brain (Alavijeh, Chishty et al. 2005; Mensch, Oyarzabal et al. 2009). Non invasive 
techniques like MRI (magnet resonance imaging) or PET (positron emission tomography) 
allow highly specific monitoring of a number of pharmacokinetic parameters. On the other 
hand they are very expensive and the tracers used show some problems in terms of stability 
(Bickel 2005; Mensch, Oyarzabal et al. 2009).  
In vitro 
Compared to in vivo techniques, in vitro experiments do not show a whole organism, but 
they allow more specific analysis of transporters, for instance. Possibilities for in vitro 
preparations are isolated brain microvessels, primary endothelial cells (human or animal) 
alone or in coculture with astrocytes, immortalized brain endothelial cells, cell lines with 
non-brain origin like Caco-2 cells (from human colon adenoma) or ECV304/C6 cells (from 
human bladder carcinoma) and non-cell based immobilized artificial membrane 
chromatography (IAM) or parallel artificial permeability assay (PAMPA). Isolated brain 
microvessels are the in vitro model closest to in vivo, but they lose activity while being 
isolated and the luminal side is difficult to assess (Mensch, Oyarzabal et al. 2009). The next 
step is isolating endothelial cells and culturing them alone or in combination with astrocytes. 
These primary cells do not have a TEER as high as in vivo and lose some of their 
characteristic properties while being extracted, but on the other hand, they do maintain 
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most of them and can be used for studying transporters (Bickel 2005; Mensch, Oyarzabal et 
al. 2009). In general the primary cells mostly used, are of bovine or porcine origine. An 
alternative to bovine and porcine cells are rats as sources, but they do not provide a 
comparable yield of cells (Cecchelli, Berezowski et al. 2007). Primary cells are very often 
used for transport studies in a transwell setting. As said before, the biggest problem is the 
low TEER. Solutions to this problem are mimicking the presence of astrocytes, as it is known 
that they interact with endothelial cells and regulate their properties. This can be done by 
culturing in astrocyte-conditioned media or co-culturing with astrocytes either in close 
proximity at the other side of the permeable membrane the endothelial cells are grown on 
or at the bottom of the well the membrane is placed in (Cecchelli, Berezowski et al. 2007). 
However, major disadvantages are the time-consuming process of isolating, seeding and 
incubating the cells (and astrocytes) and a variable reproducibility from batch to batch. As a 
result, immortalized cell lines, generated by transformation with viral proteins, are being 
developed as they overcome these problems (Bickel 2005). The most commonly used ones 
are the RBE4 line (rat) or hCMEC/D3 (human), which has been used for this study and is 
followed by a separate explanation later on. Cell lines in general can be characterised very 
well and they do express transporters, but again the TEER is a limiting factor. However, 
immortalized cell lines are usefule for biochemical and mechanistic studies. In an attempt to 
surmount the problem of the insufficient barrier properties other cell lines with non-brain 
origin have been tried, e.g. ECV304 or Caco-2. They have shown some properties of brain 
endothelial cells, but in general they cannot be used for predictions of brain permeability 
(Mensch, Oyarzabal et al. 2009). 
In silico 
Probably the most recent approach is the in silico one. Techniques in this field have evolved 
from experimental data and still rely on that. It is a promising field of research as generating 
data in a model costs significantly less effort, money and time than rendering experimental 
data (Mensch, Oyarzabal et al. 2009). A core element of in silico methods is the predicting of 
in vivo brain penetration. This can be achieved by creating screening libraries with 
compounds based on BBB permeability (Alavijeh, Chishty et al. 2005). Key features in a task 
like that are data quality and quantity, descriptors and modelling approaches (Mensch, 
Oyarzabal et al. 2009). On the other hand it is difficult to model the BBB permeability due to 
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the quality and quantity of the available data and the difficulty of creating a reasonable 
relationship between the molecular structure and the measured blood-brain partitioning 
(Mensch, Oyarzabal et al. 2009). 
 
1.1.8 hCMEC/D3 cell line 
 
The human cerebral microvascular endothelial cells / D3 are a stable immortalized cell line 
derived from human brain endothelial cells. They were transduced by lentiviral vectors 
transporting SV40 large T antigen and human telomerase reverse transcriptase (hTERT) to 
immortalize the cells. Of all the stable lines one was chosen for its expression of various 
transporters and endothelial markers e.g. von Willebrand factor and VE Cadherin, its growth 
capacity, contact inhibition at confluency and endothelial morphology. In addition this cell 
line has proved to maintain a stable phenotype throughout the course of 35 passages and 
forms capillary-like vascular cords (Weksler, Subileau et al. 2005). Additionally, the 
hCMEC/D3 cell line can be used for P-glycoprotein studies up to passage 38, afterwards the 
Pgp expression declines (Tai, Reddy et al. 2009). Although they express various tight junction 
proteins such as JAM-A and ZO-1, TEER values of cell monolayers are consistently low 
(around 40 Ω.cm2). However the cells do express functional intercellular junctions, which 
indicates that the cell line can be used for permeability studies with the exception of 
hydrophilic molecules sized smaller than 300 Da (Weksler, Subileau et al. 2005) or generally 
molecules smaller than 4 kDa (Tai, Reddy et al. 2009). The second experimental set-up for 
these cells is the drug accumulation study where the uptake of different drugs into the cells 
is measured. Again hCMEC/D3s show good values and can be used for experiments like that 
(Weksler, Subileau et al. 2005). 
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1.2 Iron chelators 
1.2.1 What is iron chelation? 
 
Iron is an essential trace mineral in the human body which can be present as Fe2+ for 
reductions or Fe 3+ for oxidations. Of the 4 – 5 grams iron in an adult about 2,5 grams can be 
found in the oxygen-transporting metalloprotein haemoglobin, about 1 gram is storage iron, 
bound to ferritin and hemosiderin, 130 milligrams are bound in myoglobin, the oxygen-
binding protein found in muscles, the labile iron pool contains 2 - 3 milligrams and 4 
milligrams appear bound to transferrin (Pschyrembel 2007; Kohgo, Ikuta et al. 2008). Usually 
the daily iron intake through normal diet is about 1 - 2 milligrams. As there is no active 
elimination pathway for iron, increased levels cannot be reduced (Galanello 2007). Normally 
iron is bound to transferrin when circulating, but when there is excessive iron supply, the 
capacity exceeds and iron is found free (Kohgo, Ikuta et al. 2008). One major problem in this 
case is the formation of radicals such as reactive oxygen species which are able to initiate 
and uphold inflammatory reactions and therefore cause tissue damage (Voest, Vreugdenhil 
et al. 1994). Another problem is the iron deposition in different organs mainly the liver, the 
heart, the brain and endocrinic glands causing dysfunction like carcinogenesis, fibrosis or cell 
death (Kohgo, Ikuta et al. 2008).  
Fig. 5 hCMEC/D3 cells at confluency, marked areas: dead 
cells  
Fig. 4 hCMEC/D3 cells in a non-confluent state, free 
spaces between the cells are visible 
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1.2.2 Structures and pharmacokinetics 
 
At present three iron chelators are licensed for clinical use, namely Deferoxamine, 
Deferiprone, and Deferasirox.  
Deferoxamine (also known as Desferrioxamine) was the first to be discovered. It has been 
the gold standard since the 1970s and saved a great number of patients with iron overload 
problems from death (Neufeld 2006; Dubey, Sudha et al. 2007). Deferoxamine is a 
hexadentate iron chelator where one molecule binds one atom of iron as ferric iron 
possesses six coordination sites which all need to be chelated in order to prevent the 
formation of radicals (Dubey, Sudha et al. 2007).  
 
It is not active orally and therefore has to be administered parenteral, usually 
subcutaneously (Neufeld 2006). The short half-life of about 20 minutes requires an infusion 
time of 8 – 12 hours applied 5 – 7 nights a week (Beutler, Hoffbrand et al. 2003). This causes 
a major compliance and logistical problem compared to oral iron chelators. Another 
disadvantage is the charging of the Deferoxamine-iron chelate, which disables it to cross 
membranes and therefore iron-induced cardiomyopathy cannot be reversed in all patients.  
In the early to mid 1980s Deferiprone (or CP20) was introduced and soon clinical studies 
began (Galanello 2007). Compared to Deferoxamine its major benefit was the ability of being 
orally active. Deferiprone is a bidentate chelator which requires three molecules to bind one 
atom of iron (Beutler, Hoffbrand et al. 2003). Resorption from the GIT is fast (15 minutes), 
plasma peak levels are 45 – 60 minutes and half-life is around 2 hours. Just 4% of the given 
oral dose is excreted bound to iron, even in heavily iron-overloaded patients (Beutler, 
 
 
Formula 1 Deferoxamine 
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 Hoffbrand et al. 2003; Dubey, Sudha et al. 2007). The Deferiprone-
iron complex is not charged, giving it the ability to remove iron 
from tissues and as a result protect the heart from toxic iron 
overload (Beutler, Hoffbrand et al. 2003; Neufeld 2006). In 
consequence of the relatively short half-life the dose of 75mg/kg, 
which is also the highest dose of all three chelators, has to be 
administered three times per day. It is eliminated via hepatic 
biotransformation as a glucuronidate and excreted with the urine 
(Galanello 2007). 
Finally Deferasirox the youngest member of this family brings some new attributes to iron 
chelators. It is a tridentate chelator with a half-life of 12 – 16 hours, peak levels are reached 
after 1 – 3 hours. Subsequently, it is sufficient to administer it once daily (Beutler, Hoffbrand 
et al. 2003; Neufeld 2006; Gattermann 2009). The dosage regimen is 20 – 30 mg/kg which is 
the lowest dose of the described iron chelators. Deferasirox-iron complexes are completely 
excreted in the stool (Neufeld 2006). Due 
to its short time on the market it has not 
been reviewed so often yet, but recent 
clinical studies have been positive about 
efficacy and cost effectiveness (Dubey, 
Sudha et al. 2007). Also data about the 
ability to bind intracellular iron in tissues 
especially in the heart are not sufficient 
yet, but laboratory studies seem promising 
(Neufeld 2006). 
 
 
 
 
 
 
Formula 2 Deferiprone 
Formula 3 Deferasirox 
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1.2.3 Fields of application – diseases treated now 
 
Iron chelators are used in treatment of iron overload caused by storage diseases or regular 
blood transfusions. In general increased iron storage and following pathological changes are 
called hemochromatosis. This definition has been modified over the years and it is still being 
discussed whether only patients who show clinical symptoms have hemochromatosis or 
already the ones who have the genotype (Beutler, Hoffbrand et al. 2003). However, a 
classification can be made into primary or hereditary and secondary hemochromatosis 
(Kohgo, Ikuta et al. 2008). Primary hemochromatosis is most commonly associated with a 
homozygous mutation of the HFE gene. Less frequent causes are juvenile hemochromatosis 
or African iron overload (Whittington and Kowdley 2002). In case of secondary 
hemochromatosis the state of iron overload is induced by blood transfusions required 
because of an anemic state of the patient. Several diseases, among others thalassemia, 
sickle-cell anemia, sideroblastic anemia or myelodysplastic syndrome can require 
transfusions to keep the patient alive (Beutler, Hoffbrand et al. 2003; Gattermann 2009). 
One millilitre blood contains about 0.5 milligrams iron (Kohgo, Ikuta et al. 2008). That means 
every transfusion unit (400 milliliters blood) contains 200 milligrams iron. A patient receiving 
3 units every four weeks will therefore cumulate 7.8 grams iron in one year. Additionally 
there is the amount of iron absorbed by the gut and normally present in the body causing a 
severe overload (Vermylen 2008).  
 
1.2.4 Application in non-iron overload states 
 
Aside from the above-mentioned diseases, iron overload in the brain is said to be 
responsible for several neurodegenerative maladies (Shachar, Kahana et al. 2004). First of all 
there are Alzheimer’s disease and Parkinson’s disease which show different clinical 
conditions but share critical processes in genesis (Molina-Holgado, Gaeta et al. 2008). 
Furthermore, rare illnesses such as Friedreich’s ataxia or Hallervorden-Spatz Syndrome show 
an iron-association in their development (Liu, Men et al. 2009). Additionally Huntington’s 
disease, which has a prevalence of about 5 to 10 cases per 100.000, but has a higher number 
of people potentially at risk, seems to be iron-dependent too (Hersch and Rosas 2008; Liu, 
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Men et al. 2009). In the past years it has become clear, that a lot of neurodegenerative 
diseases are related to age which may be directly associated with oxidative stress (Molina-
Holgado, Gaeta et al. 2008). As said before, free iron can cause the formation of radicals and 
therefore evoke oxidative stress-induced neurodegeneration (Shachar, Kahana et al. 2004). 
Treatment options for the above-mentioned diseases are mostly handicapped by the 
presence of the blood-brain barrier as the therapeutic agents should reduce iron levels in 
the brain (Liu, Men et al. 2009). Therefore the possible ability of iron chelators crossing the 
BBB is of great interest, which has been an objective in this project too. 
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2 Materials and methods 
2.1 Materials 
2.1.1 Analytical apparatus 
 
To analyse the amount of radioactivity in the cells, Perkin Elmer Liquid Scintillation Counter – 
TriCarb 2900TR, UK was used. 
The protein assay was performed on a Labsystems Multiskan Ascent plate reader, UK, and 
interpreted by Ascent software. 
HPLC was conducted on a Waters system with a 717plus Autosampler, a 2996 Photodiode 
Array Detector, a 600S Controller and a 626 Pump, all fabricated by Waters. The column 
used was a PLRP-S, 300 Å, 8 µm, 15 cm obtained from Waters. 
 
2.1.2 Cells 
 
The cells used to perform experiments, hCMEC/D3 cell line, were provided by Professor 
Couraud from the Institute Cochin, Paris, France. 
 
2.1.3 Chemicals 
 
CP20 and ethylmaltol were purchased from Sigma Aldrich, UK. 
The EGM2-bulletkit containing EGM-medium, foetal bovine serum, Insulin-like Growth 
Factor (R3-IGF-1), Vascular Endothelial Growth Factor (VEGF), recombinant human 
Endothelial Growth Factor (rhEGF) and hydrocortisone was purchased from Lonza 
(Switzerland). The factors were added as recommended by the manufacturer. Phosphate-
buffered saline (PBS-) plus calcium chloride and magnesium chloride, trypsin, basic human 
Fibroblast Growth Factor (bFGF), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES), Streptomycin and rat tail collagen were obtained by Gibco, Invitrogen, UK. All 
cultureware used, was provided by Nunc, Thermo Fisher, UK. 
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[14C]sucrose with a specific activity of 412mCi/mmol was purchased from Moravek 
Biochemicals, US. OptiPhase Hi-Safe 2 scintillation fluid was obtained by Perkin Elmer, UK. 
The reagents to perform the protein assay including the bovine serum albumin (BSA) 
standard and the reactive mix (reagent A containing sodium carbonate, sodium bicarbonate, 
bicinchoninic acid and sodium tartrate in 0.2N sodium hydroxide and reagent B which is a 
solution of 4% cupric sulphate), called BCA Protein assay, were purchased from Thermo 
Fisher, UK. 
The contents of the HPLC buffer, 1-heptanesulfonic acid and hydrochloric acid, and 
acetonitrile (HPLC gradient grade) were obtained by Fisher Scientific, UK.  
All other chemicals were supplied by Sigma Chemical Company, UK. 
 
2.2 Methods 
2.2.1 Cell culture 
 
The hCMEC/D3 were cultured in EBM-2 endothelial growth medium from the EGM-2MV 
BulletKit. The medium was supplemented with HEPES, penicillin-streptomycin, 2.5% foetal 
bovine serum, insulin-like growth factor-1, vascular endothelial growth factor, epidermal 
growth factor, hydrocortisone and basic fibroblast growth factor (Poller, Gutmann et al. 
2008). All cells used in the experiments were seeded at a density of 2.5 × 104 cells/cm2 and 
were between passage 29 and 35 (Tai, Reddy et al. 2009). Before seeding cells were checked 
for viability by 0.4 % Trypan Blue solution in a haemocytometer. Cultureware was coated 
with rat tail collagen type 1 (diluted 1:10 with sterile distilled water) for two hours prior to 
seeding. Cells were cultured in an incubator with a saturated humidity at 37˚C in 5% CO2 and 
95% fresh air and grown to 100% confluency (determined visually) for experiments 
(confluency reached after approximately 4-5 days). Protein expression (BCA™ protein assay) 
and integrity of plasma membranes ([14C]sucrose) were monitored to confirm cell viability 
(see experimental details below). At confluence the hCMEC/D3 cell line forms tight 
junctional complexes that prevent the paracellular movement of solutes with a MW in 
excess of 4 kDa (Weksler, Subileau et al. 2005; Tai, Reddy et al. 2009) and the movement of 
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solutes with lower molecular weights is unrestricted. As the present study is directed at cell 
uptake of test molecules this in vitro method is perfectly acceptable. 
Usually one T-25 and one 96-well plate have been used, the flask for gaining a stock for the 
next splitting, the plate for use in an experiment. After splitting and seeding, the cells have 
been grown in a sterile incubator at 37°C and 5% CO2 to imitate physiological conditions. The 
excess amount of cells was filled in 1 ml cryotubes, 100 µl DMSO were added and they were 
frozen at -80°C. After 24 hours the tubes were transferred into liquid nitrogen. 
 
2.2.2 Uptake assay 
 
Drug accumulation experiments were performed on confluent monolayers of hCMEC/D3s, 
grown in 60 wells of 96 well plates (Fig. 6, Fig. 7). Accumulation studies have been previously 
described (Chishty, Begley et al. 2004). A 200µl aliquot of CP20 (100, 500, 800 µM and 1mM) 
or ethylmaltol (100 and 800 µM) and [14C]sucrose (321nM) in accumulation buffer 
(consisting of 135mM NaCl, 10mM HEPES, 5.4mM KCL, 1.5mM CaCl2, 1.2mM MgCl2, 1.1mM 
2-deoxy-D-glucose, and distilled water, pH 7.4) was added to each well. Columns of well (6 
wells per column, 10 columns per plate, with n=12 for each exposure time) were exposed to 
the CP20/[14C]sucrose/buffer mix at five different time periods (5, 10, 15, 20 and 25 
minutes). This allowed assessment of drug accumulation in the cells. The accumulation 
assays were performed on a temperature-controlled shaker (THERMOstar, BMG labtech, 
Offenburg, Germany) at 37˚C and 120 rpm. 
Once each column of cells had been exposed for the correct amount of time, the wells were 
washed 3 times with ice-cold phosphate buffered saline to remove drugs and buffer that had 
not accumulated in the cells.  The cells were then lysed by adding 250µl of 1% Triton per well 
to liberate any accumulated radiolabelled drug and solubilise the cell proteins. 100 µl of each 
well was then added to a scintillation vial and 4 ml scintillation fluid (Optiphase Hisafe 2) 
added and samples counted as described previously. Hereafter 100 µl were transferred into 
an HPLC vial and 50 µl stayed in the well to perform a BCA™ protein assay.  
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Fig. 6 empty 96-well plate 
Fig. 7 schematic depiction of a 96-well plate, the red box shows the 60 
wells used in the experiment 
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2.2.3 Protein assay 
 
After lysing the cells, a protein assay was performed to establish the amount of protein in 
each well, which was used as a correction factor when calculating the amount of 
accumulated drug in the cells. It is based on the reduction of Cu2+ to Cu+ by peptide bonds in 
proteins when performed in an alkaline medium. The ion then reacts with bicinchoninic acid 
and produces a violet complex whose absorbance can be detected at 562 nm wavelength. In 
order to calculate the amount of protein found in each well, a calibration curve is made, 
based on the values from bovine serum albumin in different concentrations as standards. To 
obtain a convincing calibration curve, six different concentrations (0, 10, 15, 20, 25 and 30 
µg/100µl) are prepared from a stock solution of 2 mg/ml. 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0 0 0 E 10 10 10 E 15 15 15 E 
B E U7 U13 U19 U25 U31 U37 U43 U49 U55 U61 E 
C E U8 U14 U20 U26 U32 U38 U44 U50 U56 U62 E 
D E U9 U15 U21 U27 U33 U39 U45 U51 U57 U63 E 
E E U10 U16 U22 U28 U34 U40 U46 U52 U58 U64 E 
F E U11 U17 U23 U29 U35 U41 U47 U53 U59 U65 E 
G E U12 U18 U24 U30 U36 U42 U48 U54 U60 U66 E 
H E 30 30 30 E 25 25 25 E 20 20 20 
Table 1 schema of the array of standards 
red: standards 
green: samples 
black: empty 
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2.2.4 Cytotoxicity assay 
 
To gain an impression of how toxic the test compound is to the cells, a cytotoxicity assay can 
be performed. It uses (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, MTT 
for short, to quantify the number of viable cells. At first the cells are incubated with the 
drug, in this case CP20, for the longest time point, 24 hours, to see the maximally toxic 
effect. Then MTT is dissolved in a solution of DMEM without phenol red and applied to the 
cells. Afterwards the plate is incubated for four hours at 37°C. In this time the tetrazolium 
salt is reduced to formazan, a blue-coloured product, by the succinate dehydrogenase, a 
mitochondrial enzyme. Finally the well contents are removed by blotting the plate into the 
sink and propan-2-ol is added to dissolve the blue formazan crystals. A few minutes later the 
absorbance is read at 540 nm. To obtain a correction value, the assay is performed only on 
half of the wells, having a corresponding protein assay well for each cytotoxicity assay well. 
As the measured product is only produced in viable cells, the colour intensity decreases with 
a higher number of dead cells.  
Fig. 8 completed protein assay, the darker the colour is, the more protein is present 
37 
 
2.2.5 HPLC system 
 
100 µl of the cell lysate with Triton were transferred into an HPLC vial of which 50 µl have 
been injected into the system. 
The analysis of the drug present in the cells was made by high-pressure liquid 
chromatography (HPLC). The HPLC system consisted of an autosampler, a pump, a controller, 
a photodiode array detector and a reversed-phase polymer column. 
A linear gradient elution was applied using 1-heptanesulfonic acid sodium salt 5mM at pH 2 
(adjusted using HCl conc.) as buffer A and acetonitrile. Elution started at 2% acetonitrile and 
98% buffer and ended after 20 minutes with 35% acetonitrile, 65% buffer. To restore the 
initial conditions, 5 minutes post-run was made. The flow-rate was 1 ml/min, the 
compounds were monitored at 280 nm, room temperature (Liu, Liu et al. 1999). 
HPLC chromatograms were produced and analysed by using Millenium software. 
 
2.2.6 Statistical analysis 
 
Statistical analysis was done with GraphPad Prism using two way ANOVA. 
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3 Results 
3.1 Scintillation counter 
 
In every experiment 14C-labelled sucrose was added as a membrane integrity marker and a 
marker for non specific drug binding. To an aliquot of 100 µl cell lysate, scintillation fluid was 
added and the samples were analysed in a fluid scintillation counter. The amount of 
radioactivity was measured in disintegrations per minute (DPM). 
 
3.1.1 Influence of time points 
 
The influence of having five different time points (5, 10, 15, 20 and 25 minutes), was 
investigated by observing the sucrose values throughout that period. Therefore, three 
experiments have been chosen to give a representative depiction, shown in Fig. 9 and Fig. 10 
(values of both figures see Appendix). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sucrose DPM values 100 M CP20
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Fig. 9 The accumulation of [
14
C]sucrose by hCMEC/D3 cells in the presence of 
100µM CP20. 
DPM mean values of three experiments, 100 µM CP20, mean ± SEM error bars 
are displayed, background uncorrected, n = 3 for each time point, x-axis: time 
in minutes, y-axis: radioactivity in DPM 
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In comparison to this data, the background and the buffer have to be considered. 
Background was distilled water, 250 µl and 4 ml scintillation fluid, which had a mean value of 
46 DPM (± 10.096 SEM) and the buffer, used to incubate the cells, again 250 µl and 4 ml 
scintillation fluid, brought a mean value of 115,922.3 DPM (± 697.571 SEM). It is shown that 
the amount of radioactivity in the samples lies in the same range as the background. This 
indicates that the integrity of the cells was not violated during performing an uptake assay. 
 
 
 
 
 
 
Sucrose DPM values 800 M CP20
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Fig. 10 The accumulation of [
14
C]sucrose by hCMEC/D3 cells in the presence of 
800µM CP20. 
DPM mean values of three experiments, 800 µM CP20, mean ± SEM error bars 
are displayed, background uncorrected, n = 3 for each time point, x-axis: time 
in minutes, y-axis: radioactivity in DPM 
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3.1.2 Influence of concentration 
 
Another point of view was the presence of two different concentrations, 100 µM and 
800µM. Fig. 11 shows the direct comparison.  
 
 
Fig. 11 The comparison of [
14
C]sucrose accumulation by hCMEC/D3 cells in the presence of 100 µM and 800µM CP20. 
DPM mean values of three experiments, 100 µM and 800 µM CP20, mean ± SEM error bars are displayed, background 
uncorrected, n = 3 for each time point, x-axis: time in minutes, y-axis: radioactivity in DPM 
 
Again it is visible, that the differences seen in the diagram are very low and both curves stay 
in the range of the background values (46 DPM). The result of a two way ANOVA showed, 
that the effect of time has a significant effect on the uptake (P<0.0001), on the other hand 
the concentration does not (P=0.4452). 
It occurred that samples showed higher values than the usual average, this may have been 
caused by spills during performing the uptake assay or other mistakes due to manually 
conducted experiments. 
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3.1.3 24 hour uptake 
 
The experimental setting of a 24 hour uptake should give a higher concentration of CP20 in 
the cells, as they have a long period of time to equilibrate between buffer and cell. 
Regarding the sucrose it was assumed, that, as a marker, it would stay the same throughout 
the experiment. 
 
 
Fig. 12 The accumulation of [
14
C]sucrose by hCMEC/D3 cells over 24 hours in the presence of 0, 100, 500, 800 and 
1000µM CP20 
24 hour uptake, DPM mean values, mean ± SEM error bars are displayed, background uncorrected, x-axis: concentration 
in µM, y-axis: radioactivity in DPM 
 
As Fig. 12 shows, the more CP20 was present in the buffer, the less [14C] sucrose could enter 
the cells. This observation could lead to a conclusion about a connection between the 
penetration into the cells of [14C]sucrose and CP20 or maybe, more generally said, a 
statement about CP20’s way of penetration. At present the type of mechanism that CP20 
uses to cross the BBB is not yet known, which is a promising field to study. 
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3.2 Protein assay 
 
The protein assay was done to establish a correction factor when calculating the amount of 
drug in the cells. It gives the amount of protein in one well, which is indicative for the 
amount of cells. This value is important to know considering the fact that a higher number of 
cells could take up more drug.  
Additionally, the values can be observed throughout several experiments to monitor the 
amount of cells as a control for the performance of each experiment. Fig. 13 shows an 
example of the mean values from three experiments through the five time points (values see 
Appendix) 
 
 
Fig. 13 Comparison of amount of protein in hCMEC/D3 cells after lysis, incubated with 100 µM and 800 µM CP20. 
Protein assay values, comparison 100 µM and 800 µM CP20, n = 3 for each time point at each concentration, x-axis: time 
in minutes, y-axis: amount of protein in µg/100µl 
 
Fig. 13 shows a constant protein value around 7 µg/ 100µl, outliers like the high value at 5 
minutes with 100 µM CP20 can derive from a higher amount of cells in some wells. In cell 
culture a constant seeding density is desired, but it is not possible to ensure this and after 
seeding, the cell growth varies too.  
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3.3 HPLC 
3.3.1 CP20 in water 
 
Before analysing samples with cell lysate, the column was equilibrated (with buffer and 
acetonitrile at a flow rate of 0.2 ml/min) until the pressure was stabilised. After that CP20 
100 µM in water was injected to localize the peak. 
 
 
It was found at approximately 10.5 minutes showing a clear, symmetric peak (shown in Fig. 
14), with a well defined area under the curve (AUC). The impurities shown in red circles are 
caused by various particles in the purified water as it is impossible to remove all foreign 
compounds. Fig. 15 shows a chromatogram of water in this system, which can be seen as 
background.  
 
 
 
 
 
Fig. 14 CP20 100 µM in water, 50 µl injection volume, retention time: 10.481 minutes, 
marked in red circles are peaks of impurities caused by water 
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The corresponding UV-spectrum shows a maximum around 280 nm, this can vary a little as 
seen in Fig. 16. 
 
Fig. 16 UV-spectrum of CP20 in water 
Fig. 15 chromatogram of purified water 
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In comparison to 100 µM CP20, a lower concentration as shown in Fig. 17 also shows a 
significant peak around 10 minutes, but the impurities at 12 – 13 minutes and between 18 
and 20 minutes are proportionally bigger. 
 
 
Finally a concentration of 3 µM (Fig. 18) does show a peak at 10.5 minutes, but the 
impurities caused by water and the solvents show peaks that are higher than the 
substance’s. Therefore, other impurities, appearing at this time could easily overlap and hide 
the CP20 peak at concentrations like that. 
 
 
 
 
 
 
 
 
Fig. 17 CP20 20 µM in water, 50 µl injection volume 
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In order to be able to quantify the amount of CP20 in an unknown sample, a calibration 
curve was made using concentrations of 3, 5, 7, 10, 20, 30, 40, 50, 60, 70, 80, 90 and 100 µM 
in triplicates. As seen in Fig. 18, 3 µM can be seen as the detection limit of CP20 in this 
system, as a lower concentration might not produce an accurate peak with a measurable 
area under the curve. After analysing, the AUC was determined for each sample, mean 
values for each concentration were calculated and plotted (Fig. 19). The straight line and the 
R2 value, the coefficient of determination show that the AUC levels correlate with the 
concentrations.  
Chromatograms of all concentrations see Appendix. 
 
 
 
 
 
 
Fig. 18 CP20 3 µM in water, 50 µl injection volume 
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Fig. 19 calibration curve CP20 in water 
 
3.3.2 First experiment data 
 
After having set up the calibration curve, the first sample set was being run. Each well of the 
60 ones incubated, represented a separate sample of 100 µl cell lysate of which 50 µl have 
been injected into the HPLC. Fig. 20 shows a chromatogram of a sample incubated with 
800µM CP20 for 25 minutes, Fig. 21 shows the chromatogram of 100 µM CP20, again 
incubated for 25 minutes.  
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Fig. 21 cell lysate 100 µM CP20, 25 minutes incubation time, 50 µl injection volume 
Fig. 20 cell lysate 800 µM CP20, 25 minutes incubation time, 50 µl injection volume 
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The corresponding UV-spectrum of the peak at 12.5 minutes is shown in Fig. 22.  
 
 
Compared to the UV-spectrum in Fig. 16, a maximum at 227.4 nm occurs. In addition, the 
peak is shifted from 10.5 minutes to 12.5 minutes. This might be due to the fact that a cell 
lysate has been injected, which, compared to purified water, contains several compounds 
that might interact with CP20 and slow it down in its retention time.  
 
3.3.3 Buffer and Triton samples 
 
In order to evaluate the influence of the solutions the cells have been treated with, Triton 
and the physiological buffer used for the uptake assay have been studied separately. 
Therefore, samples of the buffer alone, 100 µM CP20 in the buffer, Triton alone and 100 µM 
CP20 in Triton have been analysed. 
 
 
Fig. 22 UV-spectrum of the peak at 12.5 minutes in Fig. 21 
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The buffer alone shows a chromatogram similar to the one of purified water concerning the 
quantity, location and height of impurity peaks. This means the buffer can be seen as 
background. 
Fig. 23 physiological buffer from uptake assay alone, 50 µl injection volume 
Fig. 24 CP20 100 µM in buffer from uptake assay, 50 µl injection volume, retention time: 10.962 minutes 
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However, 100 µM CP20 in the buffer firstly show a slight shift of the peak towards 11 
minutes and secondly the AUC is almost twice as much compared to the sample “CP20 
100µM in water”. 
Fig. 25 and Fig. 26 show the same experiment with Triton. 
 
 
 
 
Fig. 25 chromatogram Triton alone  
Fig. 26 CP20 100 µM in Triton 1%, 50 µl injection volume, retention time 10.742 minutes 
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In this case, Triton alone shows a peak at a similar time point to the peak in the experimental 
data (Fig. 21), but it shows a higher AUC. Compared to the peaks of CP20 in water, the peak 
generated by Triton alone would overlap a CP20 peak up to a concentration of 10 µM (see 
Appendix Fig. 44 to Fig. 56). 
Additionally, CP20 in Triton shows a slight delay in retention time and again it shows a much 
bigger AUC (about 2.5 times bigger than in the calibration curve). 
To get more data on how CP20 is acting in the HPLC system when dissolved in Triton, a 
calibration curve with the same concentrations as the one used for quantifying CP20 in 
water, was carried out.  
 
 
 
 
 
 
 
 
 
 
Instead of seeing a peak around 10 – 12 minutes, CP20 now appears to leave the column at a 
retention time of 6.037 minutes. In order to ensure that it is CP20, the UV-spectrum was 
checked and showed a maximum at 275.5 nm, the same as it did with CP20 in water (Fig. 
28). 
 
 
 
 
Fig. 27 CP20 100 µM in Triton, 50 µl injection volume 
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This shift was seen throughout all the samples, here an example of a concentration of 20 µM 
(Fig. 29). 
 
 
Fig. 28 UV-spectrum of the peak at 6 minutes from Fig. 27 
Fig. 29 CP20 20 µM in Triton, 50 µl injection volume 
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Furthermore, the peak was not visible after injecting a concentration lower than 20 µM (Fig. 
30), compared to the calibration curve done in water, where 3 µM CP20 were detectable. 
 
 
 
 
 
 
 
 
 
 
According to the results up to this point, a reproducible analysis of cell samples was not 
possible due to the following observations. Firstly, the peak of CP20 in presence of Triton 
was not found to be consistent in its retention time over separate experiments. Secondly, 
the UV-maximum at 227.4 nm found in the sample data could not be assigned to a 
compound in the lysate and is therefore made it harder to assure that the peak was CP20 
only without impurities. Thirdly after performing the experiments from above and analysing 
the UV-spectra, it was found that Triton-x100 has its UV-maximum at 275 nm (product 
information from Sigma) and therefore interferes with CP20 (UV-maximum at 280 nm). Due 
to this result, an accurate quantification of CP20 could not be done as it was seen impossible 
to determine the AUC of a peak by comparing the UV-spectra.  
 
 
 
 
 
Fig. 30 CP20 3 µM in Triton, injection volume 50 µl 
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3.3.4 Detergents 
 
As a result of the previous conclusions, it was the aim to find a detergent, which would not 
interfere with CP20 in the UV-spectrum.  
Limitations in that respect are:  
 a UV-maximum much lower or much higher than 280 nm 
 the ability to perform a protein assay after lysing the cells, which means the 
detergents should break up the cells, but should not break up the proteins 
 possibly not an amphiphilic detergent, as Triton is amphiphilic and this might have 
caused some of the problems in the HPLC system 
According to these principles, sodium-dodecyl sulphate (SDS), 3-[3-Cholamidopropyl)-
dimethyl-ammonio]-1-propansulphonate (CHAPS), Saponine and distilled water have been 
chosen.  
SDS is an anionic detergent, often used for separating proteins in a polyacrylamide gel 
electrophoresis (SDS-PAGE). In this setting SDS is used to unfold proteins and it is able to 
destroy the protein-DNA complex (Pang, Al-Mahrouki et al. 2006), which can therefore 
influence the amount of protein in the cells regarding the protein assay. CHAPS is a mild 
detergent and nondenaturating surfactant, designed for membrane protein purification 
(Giacomelli, Vermeer et al. 2000). Saponin is found to be a mild detergent and was chosen 
for that attribute (Mercanti and Cosson 2010), but on the other hand, it is a mixture of 
several compounds and cannot give a specific UV-spectrum. Finally distilled water can break 
up cells by osmotic lysis and has the advantage of not bringing in any additional compounds. 
In order to find the appropriate lysis buffer, the cells were incubated with all four detergents 
and additionally with Triton in order to have a control group. The concentrations used, were 
2.5% SDS in 0.2M NaOH (Guerlava, Izac et al. 1998), 1% CHAPS in 10mM TRIS (Pang, Al-
Mahrouki et al. 2006) and 10 g/l saponin in water (Wright, Finglas et al. 2000). Of the 60 
wells available, each detergent was used on 12 wells. The incubation time was 45 minutes. In 
this case ECV304 cells were used. 
The result of the protein assay is shown in Fig. 31. 
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As seen in the picture (Fig. 31), distilled water brought the result the nearest to what Triton 
did. The Triton control group had a mean protein value of 18.47 µg/100 µl. SDS showed very 
low values (mean value of -0.015 µg/100 µl) with a few below the detection limit. This result 
may be due to SDS’ ability to denature proteins and there were no protein structures left, 
which could react with bicinchoninic acid. CHAPS performed slightly better, having a mean 
value of 5.82 µg/100 µl. However, distilled water with a value of 15.33 µg/100 µl is the 
closest to the Triton results. Saponin could not be analysed as the contents of the wells 
instantly turned dark purple after adding the reactive mix, which lead to the assumption that 
the compounds themselves reacted with bicinchoninic acid and therefore disguised the 
reaction with protein compounds.  
In order to get an impression of how the detergents would react in the HPLC system, they 
have all been injected and analysed, parallel to performing the protein assay. 
 
 
 
Fig. 31 finished protein assay with five different detergents, first two rows: SDS, second: CHAPS, third: distilled water, 
fourth: saponin, fifth: Triton 
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The chromatogram of the SDS sample (Fig. 32) showed a big peak around two minutes, but 
that can be neglected regarding the fact that CP20 has a retention time of about 10.5 
minutes and SDS would therefore not interfere with the compound. The smaller peaks at 
12.5 minutes and 18.5 minutes had a low AUC and even a concentration of 3 µM CP20 could 
be detected next to them. 
 
Fig. 32 SDS 2.5% in 0.2M NaOH, 50 µl injection volume 
Fig. 33 1% CHAPS in 10mM TRIS, 50 µl injection volume 
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Comparing the samples of CHAPS (Fig. 33) and distilled water (Fig. 34), they showed a similar 
location and number of peaks, where the AUCs resembled too. As discussed earlier the 
peaks in the chromatogram of distilled water can be seen as background and therefore so 
can be the ones of CHAPS. 
 
 
Finally saponin showed a chromatogram (Fig. 35) with many peaks at various timepoints and 
with considerable AUCs in respect of the CP20 peak.  
 
 
 
 
 
 
 
 
Fig. 34 distilled water, 50 µl injection volume 
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According to the data gained in the past experiments, distilled water was chosen as lysing 
agent by reason of its good performance in the protein assay and its HPLC chromatogram 
giving the least chances of impurities which could influence CP20’s retention time. 
 
3.3.5 Results of experiments with distilled water 
 
After deciding to continue with distilled water, the procedure of an uptake assay stayed the 
same, only the lysing agent was changed.  
The experiment showed a relatively low mean value of protein concentration (2.65 µg/100 
µl) and the HPLC samples did not show a CP20 peak. Fig. 36 shows a representative sample. 
 
 
 
 
 
Fig. 35 10 g/l saponin in water, 50 µl injection volume 
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The UV-spectrum showed a similar maximum at 228.5 nm than it did in the experiment data 
with Triton. Up to this point, the maximum could not have been identified or assigned to a 
specific compound. It could be assumed, that the cells themselves may cause this maximum. 
Fig. 36 cell lysate with distilled water, 800 µM, 15 minutes incubation time, 50 µl injection volume 
Fig. 37 UV-spectrum of the peak at 12.5 minutes in Fig. 36 
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3.3.6 Additional samples 
 
This section shows additional samples that were either analysed before the realisation of the 
Triton problem or performed after in order obtain more data. 
Pooled samples 
After the first experimental data analysed by HPLC, it was the aim to make the peak CP20 
gives more visible. Therefore, samples from one sample set were pooled, taking together 6 
wells (all of the same timepoint) and then injecting 500 µl instead of 50 µl. 
 
 
 
 
The chromatogram showed a significant peak around 8 minutes, which did not show a 
symmetric AUC and after analysing the UV-spectrum of the peak (Fig. 39) could not be 
identified as CP20. 
 
 
 
Fig. 38 pooled sample, 800 µM CP20, 15 minutes incubation time, 500 µl injection volume 
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Protein precipitation 
According to the data from the pooled samples, it was tried to reduce the impurities by 
precipitating the proteins present in the cell lysate with trifluoroacetic acid. Fig. 40 shows 
the chromatogram.  
 
 
Fig. 39 UV-spectrum of the peak at 8 minutes in Fig. 38 
Fig. 40 protein precipitated, pooled sample, 800 µM CP20, 15 minutes incubation time, 50 µl injection volume 
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In this case the attempt to purify the sample resulted in getting more peaks from impurities 
instead of obtaining a better defined peak of CP20. 
 
24 hour uptake 
This experiment was done to evaluate the possibility that the chosen timepoints (5 to 25 
minutes) may have been too short for CP20 to enter the cells. The protocol for the uptake 
assay stayed the same only the incubation time was elongated to 24 hours. In order to gain 
an insight on the effects of different concentrations, 100 µM, 500 µM, 800 µM and 1 mM 
CP20 were each applied to twelve wells. Additional 12 wells were done as a control group 
without CP20. 
 
 
As seen in Fig. 41 the chromatogram did not show a significant CP20 peak. Additionally the 
end of the curve is drawn upwards, which was detected in all the samples. This phenomenon 
could be due to an accumulation of Triton in the column which could not leave the system.  
 
 
 
Fig. 41 24 hour uptake sample, 500 µM CP20, 50 µl injection volume 
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Ethylmaltol experiment 
The last experiment was done with ethylmaltol instead of CP20. Based on experiments with 
maltol and CP21, which has an additional methyl group compared to CP20 (Hider 1991), in 
multilamellar liposomes, it was suspected, that ethylmaltol would penetrate the cells very 
quickly.  
 
At first ethylmaltol’s peak in the HPLC system had to be detected. Fig. 42 shows a 
chromatogram of 100 µM ethylmaltol in water. Similar to CP20, it came out around 12 
minutes.  
Then an uptake assay was performed, following the protocol from CP20, with the 
concentrations of 100 µM and 800 µM and lysed with Triton. 
 
 
 
 
 
 
Fig. 42 ethylmaltol, 100 µM in water, 50 µl injection volume 
65 
 
 
Unfortunately the chromatogram did not show a significant peak of ethylmaltol and again 
the curve drew upwards at the end of the run. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 43 cell lysate, 800 µM ethylmaltol, 15 minutes incubation time, 50 µl injection volume 
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4 Discussion 
 
The aim of this project was to establish whether iron chelators are able to cross the human 
blood-brain barrier based on an in vitro system. 
Protecting the brain from harmful compounds is a major purpose of the BBB, which is 
important to maintain all physiological functions. On the contrary it is a difficult task to 
ensure the penetration of drugs into the brain in order to enable an optimal effect in the 
body. Therefore, permeation through the BBB is a major limitation to drug delivery and 
subsequently a promising field of research.  
Iron chelators, up to the present used in various diseases with iron overload states, are now 
considered as a valuable strategy for the treatment of neurodegenerative diseases (Hider, 
Ma et al. 2008). It has been found, that iron plays a crucial role in creating oxidative stress, 
which is a factor in the genesis of diseases like Alzheimer’s disease or Parkinson’s disease. 
Consequently it is of great interest to evaluate the possibility of transporting iron chelators 
through the BBB, in the brain. 
In vivo experiments with guinea pigs showed that CP20 can permeate the BBB and suggest 
that it passively diffuses across the endothelium (Roy 2010). To expand on this data, 
examining how the compound would act in an human setting would provide even more 
compelling information. A human endothelial cell line was chosen and incubated with a 
buffer containing CP20. The aim was to find out how much drug would accumulate in the 
cells. 
In general the experimental settings have produced valuable data except for the analysis by 
HPLC. Here it was a problem to detect CP20 because of various factors of which the choice of 
detergent was the most obstructive one. After eliminating Triton from the experimental 
setting, the search for another detergent with similar features but better performance in the 
HPLC system was done. The results from the protein assay and the HPLC analysis showed 
that distilled water, compared to SDS, CHAPS and saponin, had the best attributes to 
continue. It seemed to lyse the cells in an equivalent quality of Triton and did not interfere 
with CP20 in the HPLC chromatogram. Although distilled water seemed promising when 
tested on ECV304 cells, the protein values with hCMEC/D3 cells were significantly lower than 
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the usual average generated with Triton, which lead to the conclusion that the cells have not 
been split up completely.  
An interesting experiment was the 24 hour uptake as it showed a decreasing amount of 
radioactivity in the samples when more drug was added. Further studies may be able to find 
out how CP20 enters the cells and can therefore explain why this phenomenon occurred. In 
this project however, there was not enough time to pursue this observation more. 
As a result of the work done, a few suggestions for further experiments can be made in 
order to achieve the goal of characterising CP20’s ability to cross the BBB in an in vitro 
setting. 
 
4.1 Changes to the experimental setting 
 
As said before, the lysing agent was not ideal for an analysis with HPLC. Therefore it remains 
crucial to find a better way of lysing the cells without interfering with the HPLC 
chromatogram. An option not mentioned in this report is sonication. In this case the cells get 
ruptured by mechanical action which would not give any additional compounds that might 
produce or overlap peaks. This method needs to be coordinated with the protein assay to 
confirm the efficacy of the lysis.  
 
4.2 Changes in the cell system 
 
The hCMEC/D3 cell line was chosen because it is human and it has many features of the BBB 
in vivo. As described in various papers (Weksler, Subileau et al. 2005) the endothelial cells do 
not form a tight monolayer and have a low TEER. Therefore, the cells are not ideal for 
transwell systems which would allow measurements of transendothelial permeability. 
Nevertheless, a transwell system might help getting better results regarding the HPLC. The 
biggest advantage in this case is that the sample used, does not contain cell compounds as 
the experimental setting is focused on the drug passing through the cells, not staying in 
them. The samples would contain physiological buffer, but as seen in Fig. 23 and Fig. 24 the  
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buffer does not interfere with CP20 and can be seen as background. Here it is a difficult 
decision whether to stay close to human conditions or accept animal cells which do not 
represent the settings in the human body this accurate, but allow other techniques. In order 
to set up a transwell experiment, other cell lines, involving cells with non human origin for 
instance derived from mice or rats (Terasaki, Ohtsuki et al. 2003), are well established at 
present. 
The co-culture with astrocytes is another option, whether the endothelial cells are human or 
animal. This should improve the barrier tightness as astrocytes influence endothelial cells in 
vivo and heighten the integrity (Butt, Jones et al. 1990). Mimicking this specific influence can 
be done by co-culturing as said before or adding astrocyte conditioned culture medium to a 
culture of endothelial cells (Mensch, Oyarzabal et al. 2009). 
 
4.3 Changes in the analysis 
 
As said before, the HPLC analysis was the major problem in the experiments. In order to 
avoid this problem, it may be interesting to use other methods like radiolabelling of the 
compound or fluorescence measurements to quantify the amount of CP20 in the cells.  
Since sucrose was radiolabelled and analysed by a liquid scintillation counter, it would be a 
possibility to test a compound that is radiolabelled too. This would ease the process as the 
sample can be analysed at once and does not have to be divided and would therefore 
minimize the risk of human error. It has to be considered, that the drug used, would need to 
be labelled with another radio isotope (such as tritium) than carbon-14 in order to be able to 
count the two compounds separately.  
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5 Abstract 
 
The Blood-Brain Barrier (BBB) is an important partition of the blood circulation and the brain 
environment. It makes sure unwanted agents like xenobiotics or microorganisms cannot 
enter the brain whereas substrates needed for physiological functions are supplied in 
sufficient amounts. The pharmaceutical industry, as well as academia, have great interest in 
research on the BBB in terms of selective drug targeting. For some drugs it is important they 
do not enter the brain because if they did, it would cause sideeffects. In other cases 
penetration into the brain is essential for the drug’s effect such as therapeutical agents 
treating neurodegenerative diseases like Alzheimer’s disease or Parkinson disease. 
In order to obtain insight in the mechanisms of the BBB, various systems have been 
developed. In vitro cultures have undergone a rapid development in the past years and it 
was possible to create an immortalized human cell line of microvascular endothelial cells 
appearing at the BBB. These cells have proven to possess a large number of features which 
occur in the living human body. However, one attribute has not yet been fully mimicked with 
these cells, the ability to form the extraordinary impermeable tight junctions which are an 
important characteristic of the BBB. Therefore experiments done in this study investigated 
the drug uptake into the cells. 
The compound analysed was deferiprone (or CP20), an iron chelator widely used for diseases 
like thalassaemia where frequent blood transfusions are required. As a result the body is 
soon developing an iron overload state which, untreated, can cause death. Recent studies 
have found out that iron overload in the brain is a participant in the formation of 
neurodegenerative diseases. Hence research about iron chelators crossing the BBB is of 
great interest.  
Radiolabelled sucrose was used as a vascular space marker and a marker for non specific 
drug uptake and was analysed by a liquid scintillation counter. CP20 was analysed in an HPLC 
system. 
In the course of experiments it was discovered that the system used, had some problems 
with the analysis of the compound. It was attempted to change the lysing agent, Triton, as it 
was interfering with CP20 in the HPLC chromatogram and had the same maximum in the UV-
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spectrum. Distilled water was chosen as a replacement but it did not show more promising 
results.  
So as to vary the experimental setting and overcome the issues mentioned above, 
precipitating the proteins in the sample or pooling several samples was tried. Nevertheless 
these efforts did not show the desired effect and CP20 could not be detected or quantified 
in the chromatograms.  
An experiment worth pursuing was the 24 hour uptake, showing a decreasing amount of 
sucrose with an increasing amount of CP20. Due to a lack of time it was not analysed further 
in this study. 
Taken together the ability of CP20 crossing the BBB could not be studied in these 
circumstances, nevertheless changes in the experimental setting might bring new insights to 
this subject and therefore to treatment of neurodegenerative diseases. 
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6 Zusammenfassung 
 
Die Blut-Hirn Schranke (BHS) stellt eine wichtige Teilung zwischen Blutzirkulation und Gehirn 
dar. Sie sorgt dafür, dass nicht erwünschte Stoffe wie Xenobiotika oder Mikroorganismen 
nicht ins Gehirn kommen, Substrate, die für die physiologische Funktion erforderlich sind, 
jedoch in genügender Zahl geliefert werden. Sowohl die pharmazeutische Industrie als auch 
die universitäre Forschung sind sehr an der Erforschung der BHS bezüglich „drug targeting“ 
interessiert. Für manche Stoffe ist es wichtig, dass sie nicht ins Gehirn gelangen, da sonst 
Nebenwirkungen auftreten könnten. In anderen Fällen ist es notwendig Medikamenten 
Zutritt zum Gehirn zu verschaffen um den gewünschten Effekt zu erreichen. Beispiele dafür 
sind Pharmazeutika, die zur Therapie von neurodegenerativen Krankheiten wie Alzheimer 
oder Parkinson verwendet werden. 
Um die BHS und ihre Funktionen zu verstehen und erforschen wurden verschiedene Systeme 
entwickelt. In den vergangenen Jahren hat es eine große Entwicklung im Bereich der in vitro 
Kulturen gegeben und es war möglich eine immortalisierte, menschliche Zelllinie von 
mikrovaskulären Endothelzellen, die in der BHS vorkommen, zu erschaffen. Diese Zellen 
haben bewiesen, dass sie viele der im lebendigen, menschlichen Körper vorkommenden 
Attribute innehaben. Trotzdem gibt es bis zum heutigen Tag keine Möglichkeit die 
außergewöhnlich dichten „tight junctions“, die eine wichtige Eigenschaft der BHS darstellen, 
nachzuahmen. Deshalb wurde in dieser Studie die Aufnahme eines Stoffes in die Zellen 
untersucht. 
Der zu untersuchende Stoff war Deferipron (oder CP20), ein Eisenchelator, der weit 
verbreitet bei der Therapie von Krankheiten wie Thalassämie eingesetzt wird, wo die 
Patienten regelmäßige Bluttransfusionen benötigen. Durch diese Transfusionen stellt sich im 
Körper ein Übermaß an Eisen ein, das unbehandelt zum Tod führen kann. Neuere Studien 
belegen, dass übermäßig viel Eisen im Gehirn ein Faktor bei der Entstehung von 
neurodegenerativen Krankheiten sein kann. Daher ist die Erforschung der Möglichkeiten, wie 
Eisenchelatoren die BHS überwinden, von großer Bedeutung. 
Radioaktiv markierte Saccharose wurde als vaskulärer Gefäßmarker verwendet und durch 
einen Flüssig-Szintillationszähler vermessen. CP20 wurde auf einem HPLC-System analysiert. 
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Im Verlauf der Experimente wurde herausgefunden, dass es einige Probleme bezüglich der 
Analyse des Stoffes in dem verwendeten System gab. Daher wurde versucht, das zur Lyse 
verwendete Detergens Triton zu ändern, da es im HPLC-Chromatogramm CP20 störte und 
dasselbe UV-Maximum aufwies. Als neues Detergens wurde destilliertes Wasser genutzt, das 
aber auch nicht das gewünschte Ergebnis brachte.  
Um die Bedingungen der Experimente zu ändern und die oben beschriebenen Hindernisse zu 
überbrücken, wurde Proteinfällung oder Vereinigung mehrerer Proben versucht. Jedoch 
konnten auch diese Versuche nicht zu einer Verbesserung führen und CP20 konnte in den 
Chromatogrammen nicht detektiert oder quantifiziert werden.  
Ein weiteres Experiment, das der genaueren Untersuchung unterzogen werden könnte, ist 
das der 24-Stunden-Aufnahme, das eine verringerte Saccharose-Konzentration bei erhöhter 
CP20-Konzentration aufwies. Durch einen Mangel an Zeit wurde diese Beobachtung in dieser 
Studie nicht weiter verfolgt. 
Abschließend ist zu sagen, dass es unter diesen Umständen nicht möglich war eine Aussage 
über die Fähigkeit von CP20 die BHS zu übertreten, zu treffen. Änderungen im Aufbau der 
Experimente könnten aber neue Erkenntnisse bezüglich dieses Themas und folglich auch in 
der Therapie von neurodegenerativen Erkrankungen bringen. 
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Appendix 
1 HPLC chromatograms 
 
 
 
 
Fig. 44 CP20 3 µM in water, 50 µl injection volume 
Fig. 45 CP20 5 µM in water, 50 µl injection volume 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 46 CP20 7 µM in water, 50 µl injection volume 
Fig. 47 CP20 10 µM in water, 50 µl injection volume 
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Fig. 48 CP20 20 µM in water, 50 µl injection volume 
Fig. 49 CP20 30 µM in water, 50 µl injection volume 
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Fig. 50 CP20 40 µM in water, 50 µl injection volume 
Fig. 51 CP20 50 µM in water, 50 µl injection volume 
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Fig. 52 CP20 60 µM in water, 50 µl injection volume 
Fig. 53 CP20 70 µM in water, 50 µl injection volume 
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Fig. 54 CP20 80 µM in water, 50 µl injection volume 
Fig. 55 CP20 90 µM in water, 50 µl injection volume 
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Fig. 56 CP20 100 µM in water, 50 µl injection volume 
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2 Calibration curve AUCs 
 
calibration curve CP20 
 
   concentration: AUC: average: 
   5μM: 31581 
 
 
28948 31307 
 
33392 
 5μM: 92531 
 
 
90289 90366,33 
 
88279 
 7μM: 120901 
 
 
127722 125410,3 
 
127608 
 10μM: 185466 
 
 
194853 188152,3 
 
184138 
 20μM: 395421 
 
 
393019 392906,3 
 
390279 
 30μM: 575452 
 
 
619486 597580,3 
 
597803 
 40μM: 787764 
 
 
786988 773388,7 
 
745414 
 50μM: 967377 
 
 
993794 967121,3 
 
940193 
 60μM: 1153716 
 
 
1146018 1154411 
 
1163499 
 70μM: 1290341 
 
 
1362762 1333550 
 
1347547 
 80μM: 1561967 
 
 
1584492 1562041 
 
1539663 
 90μM: 1751993 
 
 
1697272 1721930 
 
1716525 
 100μM: 1949649 
 
 
1848424 1896597 
 
1891718 
 Table 2 AUCs of the calibration curve CP20 in water 
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3 Scintillation counter results 
 
14C DPM in hCMEC/D3 P, + 100 µM CP20 
  
Time 19.11.2009 23.11.2009 27.11.2009 total av. 
Average 
timepoints 
25 40 41 49 43,33 49,06 
25 86 83 41 70,00 
 25 64 55 49 56,00 
 25 52 31 35 39,33 
 25 49 36 35 40,00 
 25 52 47 38 45,67 
 20 48 36 40 41,33 44,44 
20 38 50 32 40,00 
 20 43 39 41 41,00 
 20 94 41 40 58,33 
 20 56 49 38 47,67 
 20 51 29 35 38,33 
 15 58 40 32 43,33 38,56 
15 44 38 38 40,00 
 15 49 41 32 40,67 
 15 42 34 33 36,33 
 15 35 33 35 34,33 
 15 39 33 38 36,67 
 10 41 48 41 43,33 41,39 
10 43 44 36 41,00 
 10 44 40 28 37,33 
 10 55 40 31 42,00 
 10 36 67 29 44,00 
 10 44 45 33 40,67 
 5 27 22 57 35,33 30,00 
5 28 24 41 31,00 
 5 29 23 35 29,00 
 5 22 23 32 25,67 
 5 22 20 33 25,00 
 5 26 34 42 34,00 
 
      average: 45,233333 39,533333 37,3 40,69 
  
Table 3 DPM values 100 µM CP20  
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14C DPM in hCMEC/D3 P, + 800  µM CP20 
  
Time 19.11.2009 23.11.2009 27.11.2009 total av. 
Average 
timepoints 
25 29 27 33 29,67 36,50 
25 23 25 53 33,67 
 25 41 34 38 37,67 
 25 44 33 40 39,00 
 25 44 48 30 40,67 
 25 45 39 31 38,33 
 20 40 33 35 36,00 37,56 
20 39 40 32 37,00 
 20 42 38 28 36,00 
 20 36 28 28 30,67 
 20 36 39 34 36,33 
 20 40 69 39 49,33 
 15 36 44 38 39,33 55,06 
15 86 40 41 55,67 
 15 125 46 41 70,67 
 15 60 72 43 58,33 
 15 51 46 36 44,33 
 15 60 68 58 62,00 
 10 40 
 
47 43,50 58,75 
10 51 54 33 46,00 
 10 50 79 38 55,67 
 10 59 47 83 63,00 
 10 62 42 39 47,67 
 10 169 56 65 96,67 
 5 40 39 45 41,33 45,44 
5 42 40 38 40,00 
 5 56 52 41 49,67 
 5 56 62 36 51,33 
 5 42 43 31 38,67 
 5 52 54 49 51,67 
 
      average: 53,2 46,103448 40,766667 46,66 
  
Table 4 DPM values 800 µM CP20 
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4 Protein assay results 
 
PA in hCMEC/D3 P, +100 µM CP20 
  Time 19.11.2009 23.11.2009 27.11.2009 Average av time  
25 5,9 9,69 3,82 6,76 6,90 
25 7,81 10,63 5 7,82 
 25 4,19 9,42 4,92 7,17 
 25 4,19 7,93 3,77 5,85 
 25 5,66 8,75 3,92 6,34 
 25 6,25 10,67 4,28 7,48 
 20 5,31 11,08 3,97 7,53 6,47 
20 5,8 10,05 4,92 7,49 
 20 4,41 7,18 3,79 5,49 
 20 7,03 7,78 3,43 5,61 
 20 5,68 7,35 4,72 6,04 
 20 4,97 7,5 5,82 6,66 
 15 5 6,22 2,61 4,42 6,73 
15 4,56 13,23 4,18 8,71 
 15 6,17 9,52 4,77 7,15 
 15 4,26 9,76 3,64 6,70 
 15 4,61 8,63 3,92 6,28 
 15 6,22 9,54 4,72 7,13 
 10 5,88 4 4,85 4,43 5,62 
10 3,75 10,05 3,74 6,90 
 10 5 8,19 3,95 6,07 
 10 4,97 6,1 3,36 4,73 
 10 4,02 7,54 3,87 5,71 
 10 5,31 6,92 4,87 5,90 
 5 4,14 10,6 4,59 7,60 8,43 
5 5,56 9,37 8,11 8,74 
 5 4,58 12,17 4,46 8,32 
 5 5,88 10,05 4,13 7,09 
 5 5,02 9,11 4,28 6,70 
 5 5,27 9,83 14,4 12,12 
  
Table 5 Protein assay values 100 µM CP20 
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PA in hCMEC/D3 P, +800 µM CP20 
  Time 19.11.2009 23.11.2009 27.11.2009 Average 
 25 4,61 10,82 7,88 9,35 7,52 
25 4,38 10,65 4,33 7,49 
 25 5,56 9,01 5,21 7,11 
 25 4,26 8,1 3,82 5,96 
 25 4,21 8,53 4,46 6,50 
 25 5,95 6,41 11,01 8,71 
 20 5,51 10,19 4,59 7,39 6,66 
20 4,46 9,78 3,2 6,49 
 20 3,38 8,77 3,38 6,08 
 20 4,41 8,68 5,77 7,23 
 20 3,09 9,04 3,69 6,37 
 20 4,7 8,31 4,51 6,41 
 15 5,14 9,11 6,23 7,67 6,75 
15 5,27 9,08 5,62 7,35 
 15 3,94 9,13 4,56 6,85 
 15 4,41 7,01 4,31 5,66 
 15 3,16 10,05 3,38 6,72 
 15 3,8 8,75 3,72 6,24 
 10 5,49 13,66 6,39 10,03 7,22 
10 4,51 9,42 8,36 8,89 
 10 4,31 9,81 4,51 7,16 
 10 3,28 9,76 4,18 6,97 
 10 3,31 5,04 3,02 4,03 
 10 5,88 7,5 4,95 6,23 
 5 5,71 9,61 4,98 7,30 6,01 
5 5,12 6,94 4,03 5,49 
 5 5,22 8,05 4,03 6,04 
 5 5,05 7,3 4,1 5,70 
 5 4,73 7,62 5,1 6,36 
 5 4,41 6,39 3,97 5,18 
  
Table 6 Protein assay values 800 µM CP20 
 
 
 
